Multivir Inc.
Oncolytic adenoviral vector expressing TGF-β decoy receptor for systemic delivery to tumors
- Sector
- Biotech
- Total capital
- $600K
- Federal grants
- $600K
- 2 awards · 2018
- Rank in peer group#54 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 14 pending · first 2021
- Rank in peer group#53 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta$300K
- Federal grantHealth and Human S · Phase I · Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#54 · top 14%
- Granted patents#53 · top 14%
- Linked publications#9 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 2 granted of 16- PendingMethods And Compositions Comprising Tumor Suppressor Gene Therapy And CD122/CD132 Agonists For The Treatment Of CancerUSPTOApplication 19369954
- GrantedMethods And Compositions Comprising Tumor Suppressor Gene Therapy And CD122/CD132 Agonists For The Treatment Of CancerUSPTOUS 12,454,561
- PendingMethods And Compositions Comprising Tumor Suppressor Gene Therapy For The Inhibition Of PathogensUSPTOApplication 18268752
Show all 16 patent records
- Methods And Compositions Comprising Tumor Suppressor Gene Therapy And CD122/CD132 Agonists For The Treatment Of CancerFeb 19, 2026 · Application 19369954Pending
- Methods And Compositions Comprising Tumor Suppressor Gene Therapy And CD122/CD132 Agonists For The Treatment Of CancerOct 28, 2025 · US 12,454,561Granted
- Methods And Compositions Comprising Tumor Suppressor Gene Therapy For The Inhibition Of PathogensFeb 8, 2024 · Application 18268752Pending
- Methods And Compositions Comprising Enhanced Targeted Immune Gene Therapy For The Treatment Of CancerJul 21, 2022 · Application 17593486Pending
- P53 BiomarkersMar 25, 2021 · Application 17112037Pending
- P53 BiomarkersJan 5, 2021 · US 10,883,993Granted
- Methods And Compositions Comprising Viral Gene Therapy And An Immune Checkpoint Inhibitor For Treatment And Prevention Of Cancer And Infectious DiseasesJan 9, 2020 · Application 16468408Pending
- Compositions Comprising Tumor Suppressor Gene Therapy And Immune Checkpoint Blockade For The Treatment Of CancerFeb 7, 2019 · Application 15773609Pending
- Methods And Compositions Comprising Turnor Suppressor Gene Therapy And Immune Checkpoint Blockade For The Treatment Of CencerApplication PCTUS2016060833Pending
- Methods And Compositions Comprising Tumor Suppressor Gene Therapy For The Inhibition Of PathogensApplication PCTUS2021073059Pending
- Methods And Compositions Comprising Tumor Suppressor Gene Therapy For The Inhibition Of PathogensApplication 63128294Pending
- Methods And Compositions Comprising Targeted And Abscopal Effects For The Treatment Of CancerApplication PCTUS2020063322Pending
- Methods And Compositions Comprising Enhanced Targeted Immune Gene Therapy For The Treatment Of CancerApplication PCTUS2020024593Pending
- Methods And Compositions Comprising Genetically Engineered Vaccines For The Treatment And Prevention Of CancerApplication PCTUS2019023003Pending
- Methods And Compositions Comprising Tumor Suppressor Gene Therapy And CD122/CD132 Agonists For The Treatment Of CancerApplication PCTUS2019022985Pending
- Methods And Compositions Comprising Viral Gene Therapy For Treatment And Prevention Of Cancer And Infectious DiseasesApplication PCTUS2017065861Pending
Recent research by its founders
- Scale‐Specific Viscoelastic Characterization of Hydrogels: Integrated AFM and Finite Element Modeling20254 cites
- Scale-Specific Viscoelastic Characterization of Hydrogels: Integrated AFM and Finite Element Modeling20250 cites
- Interpenetrating Polymer Network Hydrogels with Tunable Viscoelasticity and Proteolytic Cleavability to Direct Stem Cells In Vitro202413 cites
Related companies, and why
- Epigenos Bioscience, Inc.Similar federal contract value in Biotech · null in contracts
- Luxvitae Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Orbis MedicinesSimilar federal contract value in Biotech · null in contracts
- Karuna TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Sudo BiosciencesSimilar federal contract value in Biotech · null in contracts
- Anjon Biologics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .